Bausch Lomb Q3 Profit Turn But CAO Selling Into Rally
Bausch Lomb delivered a 54.6% EPS beat in Q3 that sent the stock rallying 24% to $20.40, but the executive overseeing the books has filed to sell over 112,000 shares into the surge. The buying thesis
Bausch + Lomb Q3 Profit Turn Meets CAO Selling
NEW YORK, October 30 —
Bausch + Lomb Corporation (BLCO) posted a 54.6% EPS beat in Q3 2026 that sparked an 8-day, 24% rally to $20.40, and the officer who oversees the company's books has filed to sell 112,015 shares into that surge, extending insider sales that began at $16.78 in August.
- Q3 EPS of $0.34 beat consensus by 54.6%; trailing twelve-month EPS remains -$0.32.
- Total debt of $5.11 billion against cash of $0.37 billion; free cash flow $323 million trailing.
- SVP, Controller and CAO Frederick Munsch proposes selling 112,015 shares after an August sale of 52,900 at $16.78.
The Beat and What It Conceals
Bausch + Lomb, a 173-year-old eye health company with roughly 13,000 employees selling contact lenses, glaucoma treatments, dry-eye drops, and cataract surgery equipment across more than a dozen countries, delivered a Q3 result that looked like a genuine earnings turn. Revenue is running at $5.32 billion, up 9.1% year-over-year, and gross margin sits at 61.4%. News coverage labeled it a 'clear profit turn' per the 8-K filed October 28. But the quarterly beat is a single data point sitting atop a volatile history: four quarters ago BLCO missed by 11.2%, then swung to a 55.9% beat, then nearly flat, then this quarter's surge. That oscillation is not a trend, it is noise that happened to resolve positively.
The Selling Pattern the CAO Is Building
The more pointed question is who is selling and when. Frederick Munsch, SVP, Controller and CAO, the executive responsible for Bausch + Lomb's financial statements, sold 52,900 shares at $16.78 in August, then filed to sell a further 112,015 shares now that the stock trades at $20.40. Net insider activity in the 90-day window shows $1.19 million in open-market sales against zero in purchases. Insider ownership of 87.3% reflects parent Bausch Health Companies' controlling stake, not broad management conviction. The officer with the deepest view of the books is, by revealed preference, reducing exposure at every available price.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BLCO | $7.3B | 17.1x | +34.7% |
| BHC | $3.3B | 2.1x | +34.8% |
| STVN | $5.5B | 24.5x | -18.8% |
| SHC | $5.3B | 17.4x | +14.4% |
| ALC | $34.4B | 18.0x | -4.2% |
| PRVA | $2.8B | 20.7x | -10.3% |
What the Next Quarter Must Show
The bull case, flagged by at least one analysis published October 30 as a recovery still unpriced in the valuation, rests on whether the profit improvement persists. At 17.2x forward P/E against a consensus price target of $21.14, the stock has nearly priced in the optimistic scenario. The number that matters next quarter is whether trailing EPS crosses into positive territory: at -$0.32 on a twelve-month basis, the company has not yet earned its way to a positive full-year figure despite the Q3 beat. Debt of $5.11 billion against $0.37 billion in cash leaves little margin for a revenue miss. Run the free Bausch + Lomb Corporation deep-dive →
Current fundamentals, valuation and filing history for Bausch + Lomb Corporation (BLCO) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Bausch Lomb beat Q3 earnings?
Yes. Bausch Lomb posted Q3 EPS of $0.34, beating consensus of $0.220 by 54.6%. The earnings beat sparked an 8-day, 24% rally that sent the stock to $20.40. However, the company's trailing twelve-month EPS remains negative at -$0.32.
Why is the Bausch Lomb CAO selling shares?
SVP, Controller and CAO Frederick Munsch filed to sell 112,015 shares at $20.40, extending insider sales that began in August at $16.78. Net insider activity in the 90-day window shows $1.19 million in open-market sales against zero purchases, suggesting the executive responsible for the books is reducing exposure at every available price.
What is Bausch Lomb's debt situation?
Bausch Lomb carries total debt of $5.11 billion against cash of $0.37 billion. The company generated $323 million in trailing free cash flow. At current leverage, the company has limited margin for error if revenue misses in coming quarters.
What does Bausch Lomb make?
Bausch Lomb is a 173-year-old eye health company with roughly 13,000 employees. It sells contact lenses, glaucoma treatments, dry-eye drops, and cataract surgery equipment across more than a dozen countries. Q3 revenue came in at $5.32 billion, up 9.1% year-over-year.
What must happen next quarter for the rally to hold?
The bull case rests on whether the Q3 profit improvement persists. At 17.2x forward P/E against a consensus price target of $21.14, the stock has nearly priced in the optimistic scenario. The key metric is whether trailing EPS finally crosses into positive territory.
Bausch + Lomb's Q3 earnings beat analyst estimates by 55% and powered an 8-day, 24% stock rally to $20.40 — yet the SVP, Controller and CAO who oversees the company's books has now filed to sell more than 112,000 additional shares at the elevated price, extending a pattern of insider selling that began near $16.50 in August.